Century Therapeutics

IPSC (NasdaqCM)

Century Therapeutics, Inc. is a biotechnology company developing allogeneic cell therapies for solid tumors, hematologic malignancies, and autoimmune diseases. Its lead program, CNTY-813, is an iPSC-derived beta islet replacement therapy with Allo-Evasion 5.0 for type 1 diabetes. It also develops CNTY-308 (CD19 CAR-iT) and CNTY-101 (iPSC-derived CAR-iNK), both engineered with Allo-Evasion for CD19-related autoimmune disease. Founded in 2018 and based in Philadelphia.